ZIOPHARM Oncology Initiates Phase 2 Study of Ad-RTS IL-12 and Palifosfamide Combination for Treatment of Advanced Breast Cancer

[at noodls] – NEW YORK, March 11, 2013 (GLOBE NEWSWIRE) — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced … more

View todays social media effects on ZIOP

View the latest stocks trending across Twitter. Click to view dashboard

See who ZIOPHARM is hiring next, click here to view